Assura shares rise as board backs £1.7 bln final bid from Sana Bidco

Published 11/06/2025, 08:22
© Reuters.

Investing.com -- Shares of Assura plc (LON:AGRP) rose more than 2% on Wednesday after the company agreed to a £1.70 billion final cash offer from Sana Bidco, a consortium backed by KKR and Stonepeak. 

The healthcare property group rejected a rival bid from Primary Health Properties plc, citing concerns over financial structure and execution risks.

Under the terms of the recommended deal, Assura shareholders would receive 60 pence in cash per share. 

They will also retain the previously declared interim dividends of 0.84 pence per share for April and July. 

Including these payments, the offer represents a premium of 39.2% to the 37.4 pence closing price on Feb. 14, the last business day before the start of the offer period.

The board of Assura said the bid from Bidco values the company at approximately £1.696 billion on a fully diluted basis. 

The final offer represents a 41.2% premium to the three-month volume-weighted average price and a 37.7% premium to the six-month average, both as of Feb. 13. 

It also reflects a 19% premium to Assura’s EPRA net tangible assets per share of 50.4 pence as of March 31.

The offer is described by the company as "best and final," meaning the financial terms will not be increased except in exceptional circumstances permitted by the Takeover Panel.

In a statement, Assura said its board conducted a full review of both proposals and concluded that Bidco’s offer provided greater certainty. 

Regulatory approvals for Bidco’s offer have been obtained from the State Administration for Market Regulation of the People’s Republic of China, the Israeli Competition Authority, and the Korea Fair Trade Commission. The offer is expected to secure all necessary clearances by the end of June.

Assura’s board unanimously recommended shareholders accept the Bidco offer and confirmed that directors with a combined 0.1% stake in the company intend to do so.

The company rejected the PHP offer, which was announced on May 16. It said the terms of the PHP proposal introduced significant financial risks, including increased leverage and refinancing obligations totaling approximately £2 billion. 

The board also raised concerns about PHP’s plan to dispose of assets, including Assura’s UK primary care properties, to reduce debt.

Other reasons cited for rejecting the PHP offer included reduced exposure to long-dated, inflation-linked leases, a strategy Assura said has supported growth. 

The board said combining with PHP would dilute this exposure, given PHP’s focus on outpatient medical real estate and shorter lease structures.

The board also warned that PHP’s integration plan, refinancing needs, and expected annual cost synergies of £15 million would create execution risk and financial uncertainty.

The Bidco offer is expected to proceed as a contractual takeover offer. An offer document is scheduled to be sent to shareholders by June 25, outlining the terms and procedure for accepting the offer.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.